Oncimmune replaces outgoing CFO
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Insight Weekly: Renewables lead capacity additions; bank mergers of equals up; nickel IPOs surge
Insight Weekly: Utilities face headwinds; S&P 500 dividend hikes likely; dollar poised for rally
Oncimmune Holdings PLC director and CFO Andrew Millet has stepped down but will remain with the company for six months to ensure an orderly transition.
The company appointed Matthew Hall to replace Millet. Hall recently served as CFO at Tusk Therapeutics and Simbec-Orion Group.
Oncimmune is an early-cancer detection company.
